NephroGenex shares rocket after lead drug found safe for heart

December 31, 2014 1:50 PM

15 0

(Reuters) - Shares of NephroGenex Inc shot up nearly nine-fold in premarket trading, a day after the drug developer said its lead drug was found to be safe in a cardiac safety study.

The oral drug, pyridorin, is being evaluated in a late-stage study in patients with diabetic nephropathy - a chronic, degenerative kidney disease caused by diabetes, which is often accompanied by heart disease.

Read more

To category page